BOSTON and LAUSANNE, Switzerland, March 6, 2023 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and the leader in data-driven medicine, today announced the University of Arkansas for Medical Sciences (UAMS), based in Little Rock, AR, will use SOPHiA GENETICS’ platform to support their clinical oncology research. Beginning this year, UAMS will implement the SOPHiA DDM™ platform to gain deeper insights into hematologic malignancies.
As the only health sciences university in the state of Arkansas and the state’s largest public employer, UAMS is a cornerstone of medical research and treatment for the state. SOPHiA DDM™ is a cloud-based platform that uses Artificial Intelligence with patented technologies and methods to synthesize next generation sequencing (NGS) data. Such synthesis is key to identifying characterizations of disease-causing mutations.
“Our mission at SOPHiA GENETICS is to democratize data-driven medicine, making it more accessible to all,” said Ken Freedman, Chief Revenue Officer, SOPHiA GENETICS. “The adoption of SOPHiA DDM™ for UAMS – Arkansas’ only health sciences university – will benefit the entire state and larger medical community by providing the institution with more comprehensive insights from their data.”
Hematologic malignancies such as leukemia, lymphoma, or plasma cell myeloma can move fast. Clinical researchers need to be able to move quickly as well. Having the ability to synthesize NGS data in-house builds local expertise and allows for faster data turnaround, a benefit to both clinical researchers and patients.
Hematological tumors represent the fourth most frequent cancer type in the developed world.1 The SOPHiA DDM™ for Blood Cancers solution is designed to accelerate and streamline the analyses of blood cancers and positively impact disease management.
“We’re excited to bring this technology to the state of Arkansas,” said Philippe Menu, Chief Medical Officer, SOPHiA GENETICS. “One person in the U.S. is diagnosed with leukemia, lymphoma, or myeloma roughly every three minutes2. The SOPHiA DDM™ for Blood Cancers solution will put increased data at the fingertips of clinical researchers.”
For more information on SOPHiA GENETICS, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn, Facebook, and Instagram. Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
UAMS is the state’s only health sciences university, with colleges of Medicine, Nursing, Pharmacy, Health Professions and Public Health; a graduate school; a hospital; a main campus in Little Rock; a Northwest Arkansas regional campus in Fayetteville; a statewide network of regional campuses; and seven institutes: the Winthrop P. Rockefeller Cancer Institute, Jackson T. Stephens Spine & Neurosciences Institute, Harvey & Bernice Jones Eye Institute, Psychiatric Research Institute, Donald W. Reynolds Institute on Aging, Translational Research Institute and Institute for Digital Health & Innovation. UAMS includes UAMS Health, a statewide health system that encompasses all of UAMS’ clinical enterprise. UAMS is the only adult Level 1 trauma center in the state. UAMS has 3,240 students, 913 medical residents and fellows, and five dental residents. It is the state’s largest public employer with more than 11,000 employees, including 1,200 physicians who provide care to patients at UAMS, its regional campuses, Arkansas Children’s, the VA Medical Center and Baptist Health. Visit www.uams.edu or uamshealth.com. Find us on Facebook, Twitter, YouTube or Instagram.